Galapagos News - GXE

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 Mechelen, Belgium; June 14...

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy...

Galapagos creates new subscription right plans

Galapagos creates new subscription right plans Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext...

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in...

Galapagos reports first quarter 2024 financial results

Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline...

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024...

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024...

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings Publication of annual report for...

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board Mechelen, Belgium; 26 March 2024, 21:01 CET;...

Galapagos announces full year 2023 results and outlook for 2024

Galapagos announces full year 2023 results and outlook for 2024 Full year 2023 key financials: Group net revenues of €783.5 million...

Galapagos presents at EBMT-EHA annual meeting 2024

Galapagos presents at EBMT-EHA annual meeting 2024 Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents...

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV...

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing...

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology Strategic...

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma Transaction expected to close in the first quarter of 2024, subject to...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Galapagos (GXE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GXE News

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Galapagos creates new subscription right plans

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

Galapagos reports first quarter 2024 financial results

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos announces full year 2023 results and outlook for 2024

Galapagos presents at EBMT-EHA annual meeting 2024

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

GXE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Galapagos (GXE) News

Galapagos (GXE)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GXE News

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Galapagos creates new subscription right plans

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

Galapagos reports first quarter 2024 financial results

Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Galapagos announces full year 2023 results and outlook for 2024

Galapagos presents at EBMT-EHA annual meeting 2024

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

GXE Discussion

Your Recent History